PhytoTech Medical Limited and MMJ Bioscience on Track for Revenues in July

Perth, May 28, 2015 AEST (ABN Newswire) - PhytoTech Medical Limited (ASX:PYL) ("PYL" or the "Company") is pleased to announce that production of MMJ Bioscience Limited's ("MMJ") proprietary, Good Manufacturing Practice ("GMP") produced cannabidiol ("CBD") capsules commenced in Switzerland on 25 May 2015.

Highlights:

- Production of MMJ's GMP-produced CBD food supplement capsules commenced 25 May 2015 - Capsules to be branded and sold as SativolTM

- SativolTM will be the first product launched by Satipharm (an MMJ subsidiary) under exclusive development alliance with Swiss partners Ai Fame gmbH and Gelpell AG

- Highly concentrated formulation derived from superior extraction processes, which result in pharmaceutical-grade quality ingredients

- Proprietary delivery technology, competitive pricing and sustainable supply to lead to strong demand in the E.U.

- Roll out of SativolTM is on schedule and expected to be available for distribution in late June 2015

- Project...

Rate this article: 
Region: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.

URL: 
http://www.abnnewswire.net/press/en/80047/PhytoTech_Medical_Limited_(ASX:PYL)_and_MMJ_Bioscience_on_Track_for_Revenues_in_July.html